Matt Kapusta, uniQure CEO
UniQure halts high-dose treatments of Huntington's drug after 3 patients hospitalized — shares tank
UniQure has been working on a gene therapy for Huntington’s disease for some time, and as the field has suffered through multiple failures, the company’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.